Results from an international IBD registry shows that steroids but not biologics (anti-TNFs) are associated with poor Covid 19 outcomes in IBD patients.
• Increasing age, comorbidities and steroid use were associated with adverse outcomes in IBD patients who contract Covid 19 infection.
• Biologic agents (like anti-TNF antagonists) does not increase the risk of hospitalization, ICU , ventilator use or death.
•The study concluded that maintaining IBD remission with steroid sparing regimen is warranted through out the pandemic.
Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry [published online ahead of print, 2020 May 18]. Gastroenterology. 2020;S0016-5085(20)30655-7. doi:10.1053/j.gastro.2020.05.032